Clinical Trial Update: Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for first-line metastatic colorectal cancer with KR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Onvansertib (onvansertib)

Snippet

Sponsor: Cardiff Oncology | Conditions: Metastatic Colorectal Cancer, CRC | Phase 2 | Status: ACTIVE_NOT_RECRUITING